ICAD: iCAD Inc. Market Cap to Revenue

Brandmark of iCAD Corp (ICAD)

iCAD, Inc. (ICAD) automates the primary analysis of images using AI, outpacing radiologists in both speed and accuracy. The historical P/S dynamics visualize the market valuation of these technologies, where 5.50 shows the current value of the metric. Business efficiency is based on the integration of software into radiology, while patents and FDA approval create significant barriers to entry for new players.

P/S Multiple: iCAD Corp (ICAD) for 07/04/2022 - 08/02/2025

Analytical breakdowns for iCAD, Inc. (ICAD)

- price and consensus price forecast:
Market Chart icadmed.com|ICAD - Analyst Consensus Forecast
- market capitalization information:
Market Valuation iCAD Corp|ICAD - Enterprise Value
- book value of equity indicators:
Book Value per Share iCAD|ICAD - Book Capitalization|Capitalization to Book Value Ratio icadmed.com|ICAD - Cumulative Company Assets
- debt obligations and liquidity statistics:
All Debt to Shareholders' Equity Ratio iCAD, Inc.|ICAD - Long-Term Debt to Capital|Short-Term Debt to Capital Coefficient icadmed.com|ICAD - Company Debts|Debt to Book Value Ratio iCAD Corp|ICAD - Company Long-Term Debts|Company Current Liabilities iCAD|Interim Coverage Ratio icadmed.com
- company profitability and valuation multiples indicators:
ICAD - Net Profit|Company Profit Forecast iCAD, Inc.|ICAD - P/E Multiple|Projected Price to Earnings icadmed.com|ICAD - PEG Multiple|EV/EBITDA Multiple iCAD Corp|ICAD - Operating profit EBITDA|Earnings per share for the last 12 months iCAD|ICAD - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months icadmed.com|ICAD - Earnings growth in current year|Earnings growth forecast for next year iCAD, Inc.
- issuer revenue and sales details:
ICAD - Company Revenue|Company Revenue Forecast icadmed.com|ICAD - P/S Multiple|Forward Price-to-Revenue Multiple iCAD Corp
Fundamental company analysis:iCAD Inc. (ICAD)
Finished products of iCAD Inc.

The P/S multiple relates the market capitalization of iCAD, Inc. (ICAD) to its annual revenue, allowing for a business valuation relative to actual sales volume without the influence of net income. By analyzing the current P/S level, an investor can determine the degree of asset overvaluation, given that high R&D costs and the slow adoption of AI diagnostics in medicine create risks for future margins.

Competing companies

Price-to-Revenue Coefficient beigene.com|P/S Multiple HALO (Halozyme)|RVMD - Market Cap to Revenue|Ascentage - P/S Multiple|CGON - P/S Multiple|URGN: P/S Multiple|Market Cap to Revenue Ratio BCAX|Market Cap to Revenue PSNL|ERAS: Market Capitalization-to-Revenue Ratio|P/S Multiple DCTH|Price-to-Revenue Coefficient Y-mAbs Corp|Price-to-Revenue Ratio Aura Biosciences, Inc. AURA|CADL: Market Cap to Revenue Ratio|Accuray - P/S Multiple|SELLAS Life Sciences (SLS) - Market Cap to Revenue|ACTU (Actuate Therapeutics, Inc) - Market Cap to Revenue|CTOR - Price-to-Revenue Coefficient|HURA (TuHURA Biosciences Inc.) - P/S Multiple|protaratx.com (TARA) - Price-to-Revenue Coefficient|P/S Multiple FATE|Market Cap to Revenue aadibio.com WHWK|P/S Multiple TCRX (TScan Therapeutics, Inc.)|P/S Multiple Champions Oncology Inc CSBR|XBiotech USA - P/S Multiple|CVM (CEL-SCI Corporation) - Market Cap to Revenue Ratio|OSTX: P/S Multiple|Market Cap to Revenue radiopharmtheranostics.com|ARTV (Artiva Biotherapeutics Inc.) - P/S Multiple|P/S Multiple Adlai Nortye Limited|Price-to-Revenue Ratio Veru Inc. (VERU)|tempesttx.com - Market Cap to Revenue Ratio|P/S Multiple XLO (Xilio Therapeutics)|RENB - Market Cap to Revenue|Mural Bio - P/S Multiple|Price to Sales Kairos Pharma Ltd|onkuretherapeutics.com (OKUR) - Price-to-Revenue Ratio|CytoMed Therapeutics Limited - Market Capitalization-to-Revenue Ratio|Market Cap to Revenue CRIS|APLM: Market Capitalization-to-Revenue Ratio|P/S Multiple THAR|Market Cap to Revenue advanbiomed.com ADVB|Genprex, Inc. - Market Cap to Revenue|P/S Multiple Calidi Biotherapeutics Inc. CLDI|SBFM - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio XBIO (Xenetic Biosciences)|SLRX: P/S Multiple|Price to Sales Kitov Pharma (PPBT)|AONC (American Oncology Network Inc) - P/S Multiple|beigene.com (BGNE) - Price-to-Revenue Coefficient|P/S Multiple CKPT|Market Cap to Revenue elevationoncology.com ELEV|P/S Multiple IKNA (Ikena Oncology)|P/S Multiple Notable Labs Corp NTBL|Viracta - P/S Multiple|MOR (morphosys.com) - Market Cap to Revenue Ratio|NAYA (NAYA Biosciences Inc.) - Market Cap to Revenue|Ascentage Pharma Group International - Market Capitalization-to-Revenue Ratio